We have updated 2013 Conferende Presentation (9 June, 2013)
We have updated 2011 publication page (16 November, 2011)
We have updated 2010 publication page (31 January, 2011)
We are soliciting donations from organizations and individuals who wish to support our activities.
For more information, please contact us.
(6 March, 2014)
JBCRG-04(CREATE-X) trial Joint-meeting has sucessfuly ended as follow, thank you very much for your attendance;
Date : February 21, Friday 2014
Place : Room Yamashiro in the Westin Miyako Kyoto
(10 February, 2014)
(6 February, 2014)
JBCRG-17TR Trial Started.
Translational research for JBCRG-17(Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer)
JBCRG-17TR Principal Investigator :
Japanese Foundation for Cancer Research Department of Genetic Diagonosis Cancer Institute
Breast Medical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research
JBCRG-17 Principal Investigator :
Dept, of Surgery, Breast Oncology, Unit Osaka National Hospital
(9 December, 2013)
Office will close during the following period.
Dec.28, 2013 ～ Jan.5, 2014
and will start on Jan.6, 2014.
(6 December, 2013)
JBCRG-M03 Trial Started
A study of eribulin in combination with trastuzumab and pertuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer
Principal Investigator :
Toshinari Yamashita (Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital)